key: cord-0259044-sfx4bf31 authors: Anderson, E. M.; Eiloa, T.; Goodwin, E.; Bolton, M. J.; Gouma, S.; Goel, R. R.; Painter, M. M.; Apostolidis, S. A.; Mathew, D.; Dunbar, D.; Fiore, D.; Brock, A.; Weaver, J.; Millar, J. S.; DerOhannessian, S.; The UPenn COVID Processing Unit,; Greenplate, A. R.; Frank, I.; Rader, D. J.; Wherry, E. J.; Hensley, S. E. title: SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations date: 2021-10-01 journal: nan DOI: 10.1101/2021.09.30.21264363 sha: 2fd61857ddb666e7969351cd41482c096af76d72 doc_id: 259044 cord_uid: sfx4bf31 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines elicit higher levels of antibodies compared to natural SARS-CoV-2 infections in most individuals; however, the specificities of antibodies elicited by vaccination versus infection remain incompletely understood. Here, we characterized the magnitude and specificity of SARS-CoV-2 spike-reactive antibodies from 10 acutely infected health care workers and 23 participants who received mRNA-based SARS-CoV-2 vaccines. We found that infection and primary mRNA vaccination elicited S1 and S2-reactive antibodies, while secondary vaccination boosted mostly S1 antibodies. Using magnetic bead-based absorption assays, we found that SARS-CoV-2 infections elicited a large proportion of original antigenic sin-like antibodies that bound efficiently to common seasonal human coronaviruses but poorly to SARS-CoV-2. In converse, vaccination only modestly boosted antibodies reactive to common seasonal human coronaviruses and these antibodies bound efficiently to SARS-CoV-2. Our data indicate that SARS-CoV-2 mRNA vaccinations elicit fundamentally different antibody responses compared to SARS-CoV-2 infections. Back boosting of β-hCoV antibodies Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines elicit higher 10 levels of antibodies compared to natural SARS-CoV-2 infections in most individuals; however, 11 the specificities of antibodies elicited by vaccination versus infection remain incompletely 12 understood. Here, we characterized the magnitude and specificity of SARS-CoV-2 spike-reactive 13 antibodies from 10 acutely infected health care workers and 23 participants who received 14 mRNA-based SARS-CoV-2 vaccines. We found that infection and primary mRNA vaccination 15 elicited S1 and S2-reactive antibodies, while secondary vaccination boosted mostly S1 16 antibodies. Using magnetic bead-based absorption assays, we found that SARS-CoV-2 infections 17 elicited a large proportion of original antigenic sin-like antibodies that bound efficiently to 18 common seasonal human coronaviruses but poorly to SARS-CoV-2. In converse, vaccination 19 only modestly boosted antibodies reactive to common seasonal human coronaviruses and these 20 antibodies bound efficiently to SARS-CoV-2. Our data indicate that SARS-CoV-2 mRNA 21 vaccinations elicit fundamentally different antibody responses compared to SARS-CoV- 2 22 infections. 23 SARS-CoV-2, antibodies, mRNA vaccines, original antigenic sin, coronavirus 25 26 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.30.21264363 doi: medRxiv preprint 6 antibody titers against β-hCoVs increase upon SARS-CoV-2 mRNA vaccination 36 . Although we 90 found small increases in OC43 FL-S antibody titers following SARS-CoV-2 mRNA vaccinations 91 ( Figure 2B) , the magnitude of OC43 FL-S antibody boosts were much lower following 92 vaccinations compared to infections for most individuals (Figure 2C) . Antibodies boosted by 93 infections and vaccinations primarily targeted the S2 domain of the OC43 spike (Figure 2A-B, 94 2D-E), with infections boosting S2 responses more effectively compared to vaccinations ( Figure 95 2E). Booster vaccinations did not affect levels of OC43 FL-S, S1, or S2 antibody levels ( Figure 96 2B-E). 97 We previously developed absorption-based assays to measure the level of cross-reactivity 101 of antibodies elicited by influenza virus infections 39 . In that study, we sequentially infected ferrets 102 with two antigenically distinct influenza virus strains and analyzed serum samples collected after 103 each infection. We found that many antibodies elicited by secondary influenza virus infections 104 paradoxically did not bind effectively to the secondary boosting influenza virus strain. We 105 proposed that antigenically distinct influenza viruses engage memory B cells elicited by prior 106 infections through multiple low affinity interactions with thousands of B cell receptors on memory 107 B cells. Low affinity antibodies secreted in a soluble form through this recall response fail to bind 108 to the antigenically distinct recall antigens because they require the level of multivalent binding 109 that is provided on B cells. 110 We developed a magnetic bead-based absorption assay to determine if OC43 FL-S 111 antibodies elicited by SARS-CoV-2 infection and vaccination cross-react with SARS-CoV-2 FL-112 S. We incubated serum samples with beads coupled with either OC43 FL-S or SARS-CoV-2 FL-113 S and then we depleted bead-reactive antibodies using a magnetic column. Then, we quantified 114 antibody levels in serum absorbed with antigen coupled beads to assess antibody cross-reactivity. 115 SARS-CoV-2 FL-S-reactive antibodies elicited by infection were efficiently depleted with SARS-116 CoV-2 FL-S coupled beads but not OC43 FL-S coupled beads ( Figure 3A) . OC43 FL-S-reactive 117 antibodies boosted by SARS-CoV-2 infection were efficiently depleted with OC43 FL-S coupled 118 beads, but surprisingly these antibodies were not depleted with SARS-CoV-2 FL-S coupled beads 119 ( Figure 3B) . These results are surprising since these OC43 FL-S-reactive antibodies were boosted 120 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in these experiments and we found that HA-reactive antibodies were not depleted with SARS-128 CoV-2 FL-S or OC43 FL-S labeled beads (Figure 3C, 3F) . Taken together, our data suggest that Here we found that polyclonal antibodies elicited by SARS-CoV-2 mRNA vaccines are at 135 a higher magnitude and have different specificities compared to those elicited by SARS-CoV-2 136 infections. We demonstrate that primary vaccinations elicit antibodies that bind to the S1 and S2 137 region of SARS-CoV-2 spike, and that S1-specific antibody responses are preferentially boosted 138 after second vaccine doses. These data are consistent with recent reports that indicate that mRNA 139 vaccinations elicit broader and more diverse antibody responses that are more effective at 140 neutralizing SARS-CoV-2 variants compared to antibodies elicited by infection 15,46-48 49 . 141 We found major differences in OC43 spike binding between antibodies elicited by SARS- . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; 8 infections and vaccinations, and that long-lived germinal centers elicited by mRNA vaccinations 50 152 are required to allow for somatic hypermutations that promote the formation of cross-reactive S2 153 antibodies that bind efficiently to the spike proteins of both β-hCoVs and SARS-CoV-2. 154 Consistent with this, a recent study found that S2-specific B cells with a memory phenotype are 155 quickly recruited following primary immunization of humans 51 156 Boosting of OC43 S2-reactive antibodies following SARS-CoV-2 infection is consistent 157 with Thomas Francis' doctrine of 'original antigenic sin' 38 . Francis found that antibodies elicited 158 by influenza vaccines often bound strongly to influenza virus strains that an individual was 159 exposed to in childhood, although it is not apparent if these recalled influenza virus antibody 160 responses typically occur at the expense of producing de novo antibodies (as we reviewed here 52 ) 161 The functional consequences of recalling low affinity S2-reactive antibodies following SARS-162 CoV-2 infections are unclear. Our previous studies found no correlation between OC43-reactive 163 antibody induction and disease outcome following SARS-CoV-2 infection 18 but a recent study 164 suggested that the recall of OC43-reactive antibodies is associated with a compromised de novo is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. Samples from Human Subjects 191 The infection cohort described in this report consists of health care workers within the 192 University of Pennsylvania Healthcare System who were recruited into a SARS-CoV-2 sero-193 monitoring study that included biweekly blood draws as previously described 16 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. (visit 4; V4). Only participants without prior SARS-CoV-2 exposure were included in this report. 207 Plasma and PBMCs were isolated from whole blood for downstream assays. 208 All sera and plasma samples were heat-inactivated in a 56 o C water bath for 1 hour prior to 209 serological testing. All samples were collected after obtaining informed consent and studies were 210 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.30.21264363 doi: medRxiv preprint Antibodies reactive to SARS-CoV-2 and OC43 antigens were quantified by enzyme-linked 238 immunosorbent assays (ELISA) as previously described 18, 54 . Absorbed sera samples were also 239 tested for the presence of influenza virus H1 HA antibodies. In brief, ELISA plates (Thermo Fisher 240 Scientific, Waltham, MA: cat. 14-245-153) were coated overnight at 4 o C with either 2 μg/mL 241 SARS-CoV-2 or influenza HA antigens, 1.5 μg/mL OC43 antigens, or Dulbecco's phosphate 242 Novavax, and Merck for work unrelated to this report. 292 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.30.21264363 doi: medRxiv preprint The first 12 months of COVID-19: a timeline of immunological insights A pneumonia outbreak associated with a new coronavirus of probable bat origin Vaccine development for emerging infectious diseases Novel approaches for vaccine development SARS-CoV-2 vaccines: a triumph of science and collaboration Messenger RNA vaccines against SARS-CoV-2 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 Neutralizing Activity of BNT162b2-Elicited Serum mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Health care worker sero-monitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration Recent endemic coronavirus infection is associated with less-severe COVID-19 Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection The dominance of human coronavirus OC43 and NL63 infections in infants Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A retrospective study in Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity Human coronavirus circulation in the United States Seasonal coronavirus protective immunity is short-lasting A human coronavirus evolves antigenically to escape antibody immunity Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients The proximal origin of SARS-CoV-2 Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic Preexisting and de novo humoral immunity to SARS-CoV-2 in humans Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit An mRNA Vaccine against SARS-CoV-2 -Preliminary Report mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. medRxiv On the Doctrine of Original Antigenic Sin Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2. medRxiv Immune history and influenza virus susceptibility A serological assay to detect SARS-CoV-2 seroconversion in humans SARS-CoV-2 seroprevalence among parturient women in Philadelphia